Colinz Laboratories Ltd
₹ 52.3
-3.58%
15 Jan
12:54 p.m.
About
Established in 1986, Colinz Laboratories is Limited is engaged in the manufacturing of Pharmaceutical Formulations like
Allopathic, Ayurvedic and Nutraceuticals in dosage forms of Tablets, Capsules, Ointments, Injectables, Syrups, etc. The company has certain specialized products for Gynecology, cardiology, gastroenterology etc.
Key Points
- Market Cap ₹ 23.9 Cr.
- Current Price ₹ 52.3
- High / Low ₹ 84.4 / 36.0
- Stock P/E 43.5
- Book Value ₹ 20.5
- Dividend Yield 0.00 %
- ROCE 7.70 %
- ROE 5.73 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 2.56 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -1.52% over past five years.
- Company has a low return on equity of 5.47% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Upcoming result date: 31 January 2025
Profit & Loss
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.18 | 7.41 | 7.88 | 8.10 | 8.05 | 7.83 | 7.59 | 7.53 | 6.16 | 6.97 | 7.15 | 7.03 | 6.95 | |
| 6.64 | 7.07 | 7.42 | 7.65 | 7.64 | 7.48 | 7.24 | 7.22 | 5.82 | 6.38 | 6.52 | 6.49 | 6.36 | |
| Operating Profit | 0.54 | 0.34 | 0.46 | 0.45 | 0.41 | 0.35 | 0.35 | 0.31 | 0.34 | 0.59 | 0.63 | 0.54 | 0.59 |
| OPM % | 7.52% | 4.59% | 5.84% | 5.56% | 5.09% | 4.47% | 4.61% | 4.12% | 5.52% | 8.46% | 8.81% | 7.68% | 8.49% |
| 0.08 | 0.13 | 0.10 | 0.10 | 0.09 | 0.10 | 0.12 | 0.13 | 0.19 | 0.17 | 0.15 | 0.28 | 0.31 | |
| Interest | 0.20 | 0.08 | 0.12 | 0.12 | 0.12 | 0.08 | 0.10 | 0.07 | 0.09 | 0.08 | 0.05 | 0.04 | 0.04 |
| Depreciation | 0.26 | 0.26 | 0.30 | 0.28 | 0.27 | 0.22 | 0.22 | 0.19 | 0.19 | 0.20 | 0.13 | 0.13 | 0.12 |
| Profit before tax | 0.16 | 0.13 | 0.14 | 0.15 | 0.11 | 0.15 | 0.15 | 0.18 | 0.25 | 0.48 | 0.60 | 0.65 | 0.74 |
| Tax % | 50.00% | 46.15% | 35.71% | 40.00% | -27.27% | -53.33% | 26.67% | 27.78% | 16.00% | 29.17% | 23.33% | 26.15% | |
| 0.08 | 0.07 | 0.10 | 0.09 | 0.14 | 0.23 | 0.12 | 0.13 | 0.21 | 0.34 | 0.46 | 0.49 | 0.55 | |
| EPS in Rs | 0.18 | 0.15 | 0.22 | 0.20 | 0.31 | 0.50 | 0.26 | 0.28 | 0.46 | 0.74 | 1.01 | 1.07 | 1.21 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -2% |
| 3 Years: | 5% |
| TTM: | -2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 33% |
| 3 Years: | 33% |
| TTM: | 17% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 40% |
| 3 Years: | 13% |
| 1 Year: | 31% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 4% |
| 3 Years: | 5% |
| Last Year: | 6% |
Balance Sheet
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.55 | 3.55 | 2.52 | 2.52 | 2.52 |
| Reserves | 2.71 | 2.78 | 2.62 | 2.71 | 2.98 | 3.21 | 3.30 | 3.29 | 3.75 | 4.14 | 5.62 | 6.43 | 6.83 |
| 2.26 | 1.88 | 2.53 | 1.80 | 0.76 | 0.42 | 0.68 | 0.38 | 0.99 | 0.48 | 0.27 | 0.57 | 0.81 | |
| 1.35 | 1.79 | 1.97 | 1.70 | 2.40 | 2.42 | 1.65 | 1.60 | 1.81 | 1.76 | 1.82 | 1.84 | 2.20 | |
| Total Liabilities | 9.86 | 9.99 | 10.66 | 9.75 | 9.68 | 9.59 | 9.17 | 8.81 | 10.10 | 9.93 | 10.23 | 11.36 | 12.36 |
| 3.98 | 3.72 | 3.16 | 2.88 | 2.63 | 2.41 | 2.21 | 2.06 | 2.03 | 1.86 | 1.71 | 1.58 | 1.51 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.32 | 0.32 | 0.29 | 0.29 | 0.41 | 0.53 | 0.50 | 0.36 | 0.61 | 0.67 | 0.66 | 1.02 | 1.14 |
| 5.56 | 5.95 | 7.21 | 6.58 | 6.64 | 6.65 | 6.46 | 6.39 | 7.46 | 7.40 | 7.86 | 8.76 | 9.71 | |
| Total Assets | 9.86 | 9.99 | 10.66 | 9.75 | 9.68 | 9.59 | 9.17 | 8.81 | 10.10 | 9.93 | 10.23 | 11.36 | 12.36 |
Cash Flows
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.15 | 0.64 | 0.09 | 0.58 | 0.06 | 0.34 | 0.12 | 0.58 | 2.16 | 0.47 | 0.40 | 1.03 | |
| 0.00 | 0.00 | 0.03 | 0.00 | -0.01 | -0.11 | -0.01 | -0.04 | -0.16 | -0.03 | 0.01 | 0.01 | |
| -0.14 | -0.37 | 0.45 | -0.73 | -0.03 | 0.01 | 0.02 | 0.06 | 0.08 | 0.09 | 0.11 | 0.23 | |
| Net Cash Flow | 0.01 | 0.27 | 0.57 | -0.16 | 0.02 | 0.24 | 0.12 | 0.60 | 2.07 | 0.52 | 0.52 | 1.27 |
Ratios
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 64.56 | 65.51 | 62.53 | 60.83 | 66.65 | 78.31 | 80.79 | 72.22 | 77.03 | 63.36 | 57.69 | 44.65 |
| Inventory Days | 237.38 | 188.53 | 288.96 | 232.18 | 267.25 | 266.31 | 246.80 | 225.13 | 208.33 | 147.59 | 149.17 | 134.31 |
| Days Payable | 51.05 | 93.17 | 116.24 | 60.66 | 55.68 | 91.93 | 44.16 | 49.29 | 90.00 | 76.17 | 103.15 | 94.81 |
| Cash Conversion Cycle | 250.89 | 160.87 | 235.25 | 232.35 | 278.23 | 252.70 | 283.42 | 248.06 | 195.36 | 134.78 | 103.71 | 84.15 |
| Working Capital Days | 113.87 | 89.65 | 110.24 | 100.04 | 105.65 | 92.30 | 122.15 | 97.43 | 58.66 | 35.09 | 25.01 | 6.75 |
| ROCE % | 4.22% | 2.51% | 3.20% | 3.23% | 3.00% | 3.18% | 3.40% | 3.39% | 4.39% | 6.80% | 8.08% | 7.70% |
Documents
Announcements
-
Board Meeting Intimation for Notice Of Date Of Board Meeting Pursuant To Regulation 29(2) Of SEBI (LODR) Regulations, 2015.
1d - Notice of Board Meeting to approve financial results.
-
Pursuant To Regulation 13 (3) Of The SEBI (Listing Obligations And Disclosure Requirement) Regulations, 2015, The Statement Of Investor Complaints Of The Company For The Quarter Ended 31St December, 2024 Is As Under
8 Jan - Investor complaints status for Q4 2024.
-
Intimation To Exchange Pursuant To Regulation 13(3) Of The SEBI (Listing Obligations And Disclosure Requirement) Regulations, 2015
8 Jan - Investor complaints status for Q4 2024.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Jan - Certificate under Regulation 74(5) for Q4 2024.
-
Declaration With Respect To Non-Applicability Of Related Party Transactions Pursuant To Regulations 23(9) Of The SEBI (LODR, Regulation 2015).
2 Jan - Declaration of non-applicability of related party transactions.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Product Portfolio:[1]
The company is manufacturing and developing a number of products for various therapeutic segments like:
a) Allopathy:[2]
The company manufactures various Oncology products like Imatinib, Erlotinib, Letrozole, etc. Anti-retroviral like Lopinavir, Indinavir, Ritonavir, etc. and also products belonging to therapeutic segments like Antibiotic; Anti pyretic Anti- Fungal, Anti-malarial, Anti-viral, etc.
b) Ayurvedics:[3]
The company manufactures many Ayurvedic products like Anti-diarrhoeals, Anti-pyretics, Anti-inflammatories, Anti-spasmodics, Cough Syrups, Apetite Stimulating Agents, Memory Boosters, Anti-piles, Antacids, Liver Tonic, etc.
c) Nutraceuticals:[4]
Major products manufactured in the Nutraceutical category are Spirulina Tabs /caps, Spirulina With Vitamins & Minerals, Omega 3 Fatty Acids Caps in Soft gel, Cod-liver Oil With Vitamin Caps in Soft Gel, Collagen, Glucosamine & Chondroitin Tabs, Amino acids tabs/caps, etc.